These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

261 related items for PubMed ID: 12743326

  • 1. Analysis of gene expression profiles in an imatinib-resistant cell line, KCL22/SR.
    Ohmine K, Nagai T, Tarumoto T, Miyoshi T, Muroi K, Mano H, Komatsu N, Takaku F, Ozawa K.
    Stem Cells; 2003; 21(3):315-21. PubMed ID: 12743326
    [Abstract] [Full Text] [Related]

  • 2. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.
    Scappini B, Gatto S, Onida F, Ricci C, Divoky V, Wierda WG, Andreeff M, Dong L, Hayes K, Verstovsek S, Kantarjian HM, Beran M.
    Cancer; 2004 Apr 01; 100(7):1459-71. PubMed ID: 15042680
    [Abstract] [Full Text] [Related]

  • 3. Ascorbic acid restores sensitivity to imatinib via suppression of Nrf2-dependent gene expression in the imatinib-resistant cell line.
    Tarumoto T, Nagai T, Ohmine K, Miyoshi T, Nakamura M, Kondo T, Mitsugi K, Nakano S, Muroi K, Komatsu N, Ozawa K.
    Exp Hematol; 2004 Apr 01; 32(4):375-81. PubMed ID: 15050748
    [Abstract] [Full Text] [Related]

  • 4. Establishment of a new Glivec-resistant chronic myeloid leukemia cell line, SNUCML-02, using an in vivo model.
    Park J, Kim KI, Koh Y, Won NH, Oh JM, Lee DS, Kim BK, Ahn KS, Yoon SS.
    Exp Hematol; 2010 Sep 01; 38(9):773-81. PubMed ID: 20438801
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
    Koch A, Scherr M, Breyer B, Mancini A, Kardinal C, Battmer K, Eder M, Tamura T.
    Oncogene; 2008 Aug 07; 27(34):4678-89. PubMed ID: 18427551
    [Abstract] [Full Text] [Related]

  • 6. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
    Barnes DJ, Palaiologou D, Panousopoulou E, Schultheis B, Yong AS, Wong A, Pattacini L, Goldman JM, Melo JV.
    Cancer Res; 2005 Oct 01; 65(19):8912-9. PubMed ID: 16204063
    [Abstract] [Full Text] [Related]

  • 7. Cytogenetic characterisation and proteomic profiling of the Imatinib-resistant cell line KCL22-R.
    Rosenhahn J, Weise A, Michel S, Hennig K, Hartmann I, Schiefner J, Schubert K, Liehr T, von Eggeling F, Loncarevic IF.
    Int J Oncol; 2007 Jul 01; 31(1):121-8. PubMed ID: 17549412
    [Abstract] [Full Text] [Related]

  • 8. Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate.
    Tipping AJ, Deininger MW, Goldman JM, Melo JV.
    Exp Hematol; 2003 Nov 01; 31(11):1073-80. PubMed ID: 14585372
    [Abstract] [Full Text] [Related]

  • 9. A novel mechanism for imatinib mesylate (STI571) resistance in CML cell line KT-1: role of TC-PTP in modulating signals downstream from the BCR-ABL fusion protein.
    Shimizu T, Miyakawa Y, Iwata S, Kuribara A, Tiganis T, Morimoto C, Ikeda Y, Kizaki M.
    Exp Hematol; 2004 Nov 01; 32(11):1057-63. PubMed ID: 15539083
    [Abstract] [Full Text] [Related]

  • 10. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
    Nguyen TK, Rahmani M, Gao N, Kramer L, Corbin AS, Druker BJ, Dent P, Grant S.
    Clin Cancer Res; 2006 Apr 01; 12(7 Pt 1):2239-47. PubMed ID: 16609040
    [Abstract] [Full Text] [Related]

  • 11. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
    Rahmani M, Nguyen TK, Dent P, Grant S.
    Mol Pharmacol; 2007 Sep 01; 72(3):788-95. PubMed ID: 17595328
    [Abstract] [Full Text] [Related]

  • 12. Effects of carboxyamidotriazole on in vitro models of imatinib-resistant chronic myeloid leukemia.
    Alessandro R, Fontana S, Giordano M, Corrado C, Colomba P, Flugy AM, Santoro A, Kohn EC, De Leo G.
    J Cell Physiol; 2008 Apr 01; 215(1):111-21. PubMed ID: 17924401
    [Abstract] [Full Text] [Related]

  • 13. BCR-ABL- and Ras-independent activation of Raf as a novel mechanism of Imatinib resistance in CML.
    Hentschel J, Rubio I, Eberhart M, Hipler C, Schiefner J, Schubert K, Loncarevic IF, Wittig U, Baniahmad A, von Eggeling F.
    Int J Oncol; 2011 Sep 01; 39(3):585-91. PubMed ID: 21637917
    [Abstract] [Full Text] [Related]

  • 14. Antileukemic activity of lysophosphatidic acid acyltransferase-beta inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib.
    La Rosée P, Jia T, Demehri S, Härtel N, de Vries P, Bonham L, Hollenback D, Singer JW, Melo JV, Druker BJ, Deininger MW.
    Clin Cancer Res; 2006 Nov 01; 12(21):6540-6. PubMed ID: 17085669
    [Abstract] [Full Text] [Related]

  • 15. Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line.
    Ricci C, Scappini B, Divoky V, Gatto S, Onida F, Verstovsek S, Kantarjian HM, Beran M.
    Cancer Res; 2002 Nov 01; 62(21):5995-8. PubMed ID: 12414617
    [Abstract] [Full Text] [Related]

  • 16. Resistance to imatinib of bcr/abl p190 lymphoblastic leukemia cells.
    Mishra S, Zhang B, Cunnick JM, Heisterkamp N, Groffen J.
    Cancer Res; 2006 May 15; 66(10):5387-93. PubMed ID: 16707466
    [Abstract] [Full Text] [Related]

  • 17. BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.
    Brauer KM, Werth D, von Schwarzenberg K, Bringmann A, Kanz L, Grünebach F, Brossart P.
    Cancer Res; 2007 Jun 01; 67(11):5489-97. PubMed ID: 17545631
    [Abstract] [Full Text] [Related]

  • 18. Resistance to targeted therapy in chronic myelogenous leukemia.
    Hochhaus A, Erben P, Ernst T, Mueller MC.
    Semin Hematol; 2007 Jan 01; 44(1 Suppl 1):S15-24. PubMed ID: 17292737
    [Abstract] [Full Text] [Related]

  • 19. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
    Wei Y, Hardling M, Olsson B, Hezaveh R, Ricksten A, Stockelberg D, Wadenvik H.
    Ann Hematol; 2006 Dec 01; 85(12):841-7. PubMed ID: 17006667
    [Abstract] [Full Text] [Related]

  • 20. Cytogenetic and molecular mechanisms of resistance to imatinib.
    Hochhaus A.
    Semin Hematol; 2003 Apr 01; 40(2 Suppl 2):69-79. PubMed ID: 12783379
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.